专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2002064568A1 PYRIDINE MATRIX METALLOPROTEINASE INHIBITORS 审中-公开
标题翻译：吡啶基金属蛋白酶抑制剂
公开(公告)号：WO2002064568A1
公开(公告)日：2002-08-22
申请号：PCT/IB2002/000345
申请日：2002-02-04
申请人： WARNER-LAMBERT COMPANY , BARVIAN, Nicole, Chantel , CONNOR, David, Thomas , O'BRIEN, Patrick, Michael , ORTWINE, Daniel, Fred , PATT, William, Chester , SHULER, Kevon, Ray , WILSON, Michael, William
发明人： BARVIAN, Nicole, Chantel , CONNOR, David, Thomas , O'BRIEN, Patrick, Michael , ORTWINE, Daniel, Fred , PATT, William, Chester , SHULER, Kevon, Ray , WILSON, Michael, William
IPC分类号： C07D213/80
CPC分类号： C07D213/80 , C07D213/81 , C07D213/82 , C07D231/12 , C07D233/56 , C07D249/08 , C07D401/14 , C07D405/14 , C07D409/14
摘要： Selective MMP-13 inhibitors are pyridine derivatives of the formula (I) or a pharmaceutically acceptable salt thereof, wherein: R 1 and R 2 independently are hydrogen, halo, hydroxy, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, NO 2 , NR 4 R 5 , CN, or CF 3 ; E is independently O or S; A and B independently are OR 4 or NR 4 R 5 ; R 4 and R 5 independently are H, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, (CH 2 ) n aryl, (CH 2 ) n cycloalkyl, (CH 2 ) n heteroaryl, or R 4 and R 5 when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring containing carbon atoms and optionally containing a heteroatom selected from O, S, or NH, and optionally substituted or unsubstituted; n is 0 to 6.
摘要翻译：选择性MMP-13抑制剂是式（I）的吡啶衍生物或其药学上可接受的盐，其中：R 1和R 2独立地是氢，卤素，羟基，C 1 -C 6烷基，C 1 -C 6烷氧基， C 2 -C 6烯基，C 2 -C 6炔基，NO 2，NR 4 R 5，CN或CF 3; E独立地为O或S; A和B分别是OR 4或NR 4 R 5; R 4和R 5独立地是H，C 1 -C 6烷基，C 2 -C 6烯基，C 2 -C 6炔基，（CH 2）n芳基，（CH 2）n环烷基，（CH 2）n杂芳基或R 4 和R 5与它们所连接的氮原子一起形成含有3至8元环的碳原子并且任选地含有选自O，S或NH的杂原子，并且任选地被取代或未取代; n为0〜6。

2. 发明申请

WO2013067274A1 HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY 审中-公开
标题翻译：作为BTK活性抑制剂的异丁基吡咯烷酮和AZA-吡咯烷酮化合物
公开(公告)号：WO2013067274A1
公开(公告)日：2013-05-10
申请号：PCT/US2012/063194
申请日：2012-11-02
申请人： GENENTECH, INC. , CRAWFORD, James John , ORTWINE, Daniel Fred , WEI, BinQing , YOUNG, Wendy B.
发明人： CRAWFORD, James John , ORTWINE, Daniel Fred , WEI, BinQing , YOUNG, Wendy B.
IPC分类号： C07D471/04 , C07D471/14 , C07D487/04 , C07D495/04 , C07D519/00 , A61K31/4985 , C07D487/14 , A61K31/381 , A61K31/4353 , A61P35/00 , A61P37/00
CPC分类号： A61K31/4985 , A61K31/495 , A61K31/496 , A61K31/4995 , A61K31/501 , A61K31/5025 , A61K31/506 , A61K31/53 , A61K31/5377 , A61K31/5383 , A61K45/06 , C07D471/04 , C07D471/14 , C07D487/04 , C07D487/08 , C07D487/14 , C07D495/04 , C07D495/14 , C07D498/04 , C07D513/04 , C07D519/00
摘要： Heteroaryl pyridone and aza-pyridone compounds of Formula I are provided, where one or two of X 1 , X 2 , and X 3 are N, and including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
摘要翻译：提供式I的杂芳基吡啶酮和氮杂 - 吡啶酮化合物，其中X1，X2和X3中的一个或两个为N，并且包括可用于抑制Btk激酶和用于治疗免疫疾病的立体异构体，互变异构体及其药学上可接受的盐例如由Btk激酶介导的炎症。公开了使用式I化合物进行体外，原位和体内诊断以及哺乳动物细胞或相关病理学条件下的这些疾病的治疗的方法。

3. 发明申请

WO2002064572A1 QUINAZOLINES AS MMP-13 INHIBITORS 审中-公开
标题翻译：喹唑啉作为MMP-13抑制剂
公开(公告)号：WO2002064572A1
公开(公告)日：2002-08-22
申请号：PCT/EP2002/001979
申请日：2002-02-11
申请人： WARNER-LAMBERT COMPANY , ANDRIANJARA, Charles , CHANTEL-BARVIAN, Nicole , GAUDILLIERE, Bernard , JACOBELLI, Henri , ORTWINE, Daniel, Fred , PATT, William, Chester , PHAM, Ly , KOSTLAN, Catherine, Rose , WILSON, Michael, William
发明人： ANDRIANJARA, Charles , CHANTEL-BARVIAN, Nicole , GAUDILLIERE, Bernard , JACOBELLI, Henri , ORTWINE, Daniel, Fred , PATT, William, Chester , PHAM, Ly , KOSTLAN, Catherine, Rose , WILSON, Michael, William
IPC分类号： C07D239/96
CPC分类号： C07D401/06 , A61K31/517 , A61K31/519 , A61K31/525 , C07D239/95 , C07D239/96 , C07D401/10 , C07D401/12 , C07D403/10 , C07D403/12 , C07D405/12 , C07D405/14 , C07D409/12 , C07D409/14 , C07D413/10 , C07D471/04
摘要： A compound selected from those of formula (I): in which: R 1 represents a group selected from hydrogen, amino, alkyl, alkenyl, aminoalkyl, aryl, arylalkyl, heterocycle, and cycloalkylalkyl, optionally substituted, W represents oxygen, sulphur, or =N-R', in which R' is as defined in the description, X 1 , X 2 and X 3 represent nitrogen or -C-R 6 in which R 6 is as defined in the description, Y represents oxygen, sulphur, -NH, or -N(C 1 -C 6 )alkyl, Z represents oxygen, sulphur, -NR 7 in which R 7 is as defined in the description, and optionally carbon atom, n is an integer from 1 to 8 inclusive, Z 1 represents -CR 8 R 9 wherein R 8 and R 9 are as defined in the description, A represents aromatic or non-aromatic, heterocyclic or non-heterocyclic ring system, m is an integer from 0 to 7 inclusive, the group(s) R 2 is (are) is as defined in the description, R 3 represents hydrogen, alkyl, alkenyl, alkynyl, or a group of formula: in which Z 2 , B, R 5 , P and q are as defined in the description, optionally, the racemic forms thereof, isomers thereof, N-oxydes thereof, and the pharmaceutically acceptable salts thereof, and medicinal products containing the same are useful as specific inhibitors of type-13 matrix metalloprotease.
摘要翻译：选自式（I）的化合物：其中：R1表示选自氢，氨基，烷基，烯基，氨基烷基，芳基，芳基烷基，杂环和环烷基烷基的基团，任选取代的W表示氧，硫或= N-R'，其中R'如说明书中所定义，X 1，X 2和X 3表示氮或-C-R 6，其中R 6如说明书中所定义，Y表示氧，硫，-NH或-N （C 1 -C 6）烷基，Z表示氧，硫，-NR 7，其中R 7如说明书中所定义，并且任选地为碳原子，n为1-8以下的整数，Z1表示-CR8R9，其中R8和R9为 A描述芳族或非芳族，杂环或非杂环环系，m是0至7的整数，包括端值在内，R2是（是）如说明书中所定义，R 3表示氢，烷基，烯基，炔基或下式的基团：其中Z2，B，R5，P和q如说明书中所定义，任选地，外消旋其形式，其异构体，N-氧化物及其药学上可接受的盐，以及含有它们的药物可用作13型基质金属蛋白酶的特异性抑制剂。

4. 发明申请

WO2004014869A3 5,6-FUSED 3,4-DIHYDROPYRIMIDINE-2-ONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS 审中-公开
标题翻译：作为基质金属蛋白酶抑制剂的5,6-FUSED 3,4-二羟基嘧啶-2-酮衍生物
公开(公告)号：WO2004014869A3
公开(公告)日：2004-06-17
申请号：PCT/IB0303534
申请日：2003-08-04
申请人： WARNER LAMBERT CO , NAHRA JOE , O'BRIEN PATRICK MICHAEL , ORTWINE DANIEL FRED
发明人： NAHRA JOE , O'BRIEN PATRICK MICHAEL , ORTWINE DANIEL FRED
IPC分类号： A61P29/00 , C07D239/74 , C07D239/80 , C07D401/06 , C07D401/12 , C07D403/06 , C07D405/06 , C07D471/04 , C07D521/00 , A61K31/517 , A61K31/519
CPC分类号： C07D231/12 , C07D233/56 , C07D239/74 , C07D239/80 , C07D249/08 , C07D401/06 , C07D401/12 , C07D403/06 , C07D405/06 , C07D471/04
摘要： This invention provides compounds defined by Formula I or a pharmaceuticafy acceptable salt theme, wherein R , Q, Y , Y , Y , Y , Y , R , and R are as defined in the specification. The invention also provides pharmaceutical compositions comprising a compounnd of Formula I and the use of the compounds of Formula I as matrix metalloproteinase inhibitors.
摘要翻译：本发明提供由式I定义的化合物或药学上可接受的盐主题，其中R 1，Q 3，Y 3，Y 4，Y 5，Y 6，Y 8， 2>和R 4如说明书中所定义。本发明还提供包含式I的化合物的药物组合物和式I化合物作为基质金属蛋白酶抑制剂的用途。

5. 发明申请

WO2002064598A1 THIENO'2,3-D PYRIMIDINDIONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS 审中-公开
标题翻译： THIENO'2,3-D吡啶衍生物作为基质金属蛋白酶抑制剂
公开(公告)号：WO2002064598A1
公开(公告)日：2002-08-22
申请号：PCT/IB2002/000204
申请日：2002-01-18
申请人： WARNER-LAMBERT COMPANY , HARTER, William, Glen , LI, Jie, Jack , ORTWINE, Daniel, Fred , SHULER, Kevon, Ray , YUE, Wen-Song
发明人： HARTER, William, Glen , LI, Jie, Jack , ORTWINE, Daniel, Fred , SHULER, Kevon, Ray , YUE, Wen-Song
IPC分类号： C07D495/04
CPC分类号： C07D487/04 , A61K31/519 , C07D491/04 , C07D495/04
摘要： Selective MMP-13 inhibitors are fused pyrimidinones of the formula or a pharmaceutically acceptable salt thereof, wherein: W, together with the carbon atoms to which it is attached, form a 5-membered ring diradical Y is O, S, SO, SO 2 , NR 5 , or CH¿2, ?A is-C-or S-; B is O or NR 5 ; or A and B are taken together to form -C≡C-; R 1 , R 4 , and R 5 are hydrogen, alkyl, alkenyl, alkynyl, (CH 2 ) n aryl, (CH 2 ) n cycloalkyl, C 1 C 6 alkanoyl, or (CH 2 ) n heteroaryl; R 2 and R 3 are hydrogen, alkyl, alkenyl, alkynyl CN, NO 2 , NR 4 R 5 , (CH 2 ) n cycloalkyl, (CH 2 ) n aryl, or (CH 2 ) n heteroaryl; R 2 may further be halo; n is an integer of from 0 to 5; and R 4 and R 5 when taken together with the nitrogen to which they are attached complete a 3-to 8-membered ring containing carbon atoms and optionally containing O, S, or N, and substituted or unsubstituted; with the proviso that R?1 ¿and R 3 are not both selected from hydrogen and C 1- C 6 alkyl.
摘要翻译：选择性MMP-13抑制剂是下式的稠合嘧啶酮或其药学上可接受的盐，其中：W与其连接的碳原子一起形成5元环双基Y是O，S，SO，SO 2， NR 5，或CH 2，A是-C-或S-; B是O或NR 5; 或A和B一起形成-CC-; R 1，R 4和R 5是氢，烷基，烯基，炔基，（CH 2）n芳基，（CH 2）n环烷基，C 1 -C 6烷酰基或（CH 2）n杂芳基; R 2和R 3是氢，烷基，烯基，炔基CN，NO 2，NR 4 R 5，（CH 2）n环烷基，（CH 2）n芳基或（CH 2）n杂芳基; R 2还可以是卤素; n为0〜5的整数。和R 4和R 5与它们所连接的氮原子一起形成含有碳原子的3-8元环，任选地含有O，S或N以及取代或未取代的; 条件是R 1和R 3不都选自氢和C 1 -C 6烷基。

6. 发明申请

WO0112592A2 HYDROXAMIC ACID COMPOUNDS USEFUL AS MATRIX METALLOPROTEINASE INHIBITORS 审中-公开
标题翻译：用作基质金属蛋白酶抑制剂的羟肟酸化合物
公开(公告)号：WO0112592A2
公开(公告)日：2001-02-22
申请号：PCT/US0021884
申请日：2000-08-10
申请人： WARNER LAMBERT CO , CONRAD CHRISTOPHER ALAN , BRIEN PATRICK MICHAEL O , ORTWINE DANIEL FRED , PICARD JOSEPH ARMAND , SLISKOVIC DRAGO ROBERT
发明人： CONRAD CHRISTOPHER ALAN , O'BRIEN PATRICK MICHAEL , ORTWINE DANIEL FRED , PICARD JOSEPH ARMAND , SLISKOVIC DRAGO ROBERT
IPC分类号： A61K31/18 , A61K31/196 , A61K31/198 , A61K31/343 , A61K31/351 , A61P1/02 , A61P9/00 , A61P9/04 , A61P9/08 , A61P9/10 , A61P9/14 , A61P13/12 , A61P17/02 , A61P19/02 , A61P19/10 , A61P21/00 , A61P21/04 , A61P25/00 , A61P25/14 , A61P25/16 , A61P25/28 , A61P27/02 , A61P29/00 , A61P31/18 , A61P35/00 , A61P37/02 , A61P43/00 , C07C311/19 , C07C311/20 , C07D307/91 , C07D307/93 , C07D407/12
CPC分类号： C07D307/91 , C07C311/19 , C07C311/20 , C07C2601/08 , C07C2601/14 , C07D307/93 , C07D407/12
摘要： Compounds of formula (I), are useful for inhibiting matrix metalloproteinase enzymes in animals, and as such, prevent and treat diseases resulting from the breakdown of connective tissues. Also disclosed are methods for the preparation of such compounds, pharmaceutical compositions including the same, and methods of treating diseases in which matrix metalloproteinases are involved including multiple sclerosis, atherosclerotic plaque rupture, restenosis, aortic aneurysm, heart failure, periodontal disease, corneal ulceration, burns, decubital ulcers, chronic ulcers or wounds, cancer metastasis, tumor angiogenesis, osteoporosis, rheumatoid or osteoarthritis, renal disease, left ventricular dilation, or other autoimmune or inflammatory diseases dependent upon tissue invasion by leukocytes.
摘要翻译：式（I）化合物可用于抑制动物中的基质金属蛋白酶，并因此预防和治疗由结缔组织分解导致的疾病。还公开了用于制备这样的化合物的方法，包含其的药物组合物，以及涉及基质金属蛋白酶参与的疾病的方法，包括多发性硬化症，动脉粥样硬化斑块破裂，再狭窄，主动脉瘤，心力衰竭，牙周病，角膜溃疡，烧伤，褥疮溃疡，慢性溃疡或伤口，癌症转移，肿瘤血管生成，骨质疏松症，类风湿或骨关节炎，肾脏疾病，左心室扩张或其他自身免疫或炎性疾病，这些疾病取决于白细胞的组织侵入。

7. 发明申请

WO2014023258A1 PYRAZOLE CARBOXAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE 审中-公开
标题翻译：吡唑羧酰胺化合物，组合物和使用方法
公开(公告)号：WO2014023258A1
公开(公告)日：2014-02-13
申请号：PCT/CN2013/081136
申请日：2013-08-09
申请人： F.HOFFMANN-LA ROCHE AG , GENENTECH, INC. , BROOKFIELD, Frederick , BURCH, Jason , GOLDSMITH, Richard A. , HU, Baihua , LAU, Kevin Hon Luen , MACKINNON, Colin H. , ORTWINE, Daniel Fred , PEI, Zhonghua , WU, Guosheng , YUEN, Po-wai , ZHANG, Yamin
发明人： BROOKFIELD, Frederick , BURCH, Jason , GOLDSMITH, Richard A. , HU, Baihua , LAU, Kevin Hon Luen , MACKINNON, Colin H. , ORTWINE, Daniel Fred , PEI, Zhonghua , WU, Guosheng , YUEN, Po-wai , ZHANG, Yamin
IPC分类号： C07D231/56 , A61K31/416 , A61P37/00
CPC分类号： C07D403/12 , C07D401/14 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D487/10 , C07D491/044 , C07D491/10 , C07D491/107 , C07D495/10 , Y02P20/582
摘要： Provided herein are compounds of formula (AA): N N H HN O N N R R 6 A (R a ) p, (AA) stereoisomers or a pharmaceutically acceptable salt thereof, wherein A, R a, p, R and R 6 are defined herein, compositions including the compounds and methods of manufacturing and using the compounds for the treatment of diseases.
摘要翻译：本文提供了式（AA）的化合物：其中A，R a，p，R和R 6如本文所定义，其组合物包括：制备和使用化合物治疗疾病的化合物和方法。

8. 发明申请

WO2005000818A1 5-SUBSTITUTED-4-`(SUBSTITUTED PHENYL)!AMINO!-2-PYRIDONE DEVIATIVES FOR USE AS MEK INHIBITORS 审中-公开
标题翻译： 5-取代的-4'-（取代的苯基）！用于MEK抑制剂的氨基-2-吡啶酮衍生物
公开(公告)号：WO2005000818A1
公开(公告)日：2005-01-06
申请号：PCT/IB2004/002060
申请日：2004-06-18
申请人： WARNER-LAMBERT COMPANY LLC , BLACK, Shannon, Leigh , KAUFMAN, Michael, David , ORTWINE, Daniel, Fred , PLUMMER, Mark, Stephen , QUIN, John, III , REWCASTLE, Gordon, William , SHAHRIPOUR, Aurash, Bavarsad , SPICER, Julie, Ann , WHITEHEAD, Christopher, Emil
发明人： BLACK, Shannon, Leigh , KAUFMAN, Michael, David , ORTWINE, Daniel, Fred , PLUMMER, Mark, Stephen , QUIN, John, III , REWCASTLE, Gordon, William , SHAHRIPOUR, Aurash, Bavarsad , SPICER, Julie, Ann , WHITEHEAD, Christopher, Emil
IPC分类号： C07D213/78
CPC分类号： C07D213/78 , C07D213/80 , C07D213/82 , C07D213/87 , C07D401/12 , C07D413/04
摘要： The present invention relates to 5-substituted-4-(substituted) phenylamino-2-pyridone derivatives of formula (I), pharmaceutical compositions and methods of use thereof as MEK inhibitors. Formula (I) wherein W is formula (II), formula (III), formula (IV), or formula (V); and R 1-5 and Z are as defined in the claims.
摘要翻译：本发明涉及式（I）的5-取代-4-（取代）苯基氨基-2-吡啶酮衍生物，药物组合物及其用作MEK抑制剂的方法。式（I）其中W是式（II），式（III），式（IV）或式（V）; R1-5和Z如权利要求中所定义。

9. 发明申请

WO2004014880A1 CHROMONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS 审中-公开
标题翻译： CHROMONE衍生物作为基质金属蛋白酶抑制剂
公开(公告)号：WO2004014880A1
公开(公告)日：2004-02-19
申请号：PCT/IB2003/003541
申请日：2003-08-04
申请人： WARNER-LAMBERT COMPANY LLC , ORTWINE, Daniel, Fred
发明人： ORTWINE, Daniel, Fred
IPC分类号： C07D265/22
CPC分类号： C07D311/22 , C07D265/22
摘要： This invention provides compounds defined by Formula I or a pharmaceutically acceptable salt thereof, wherein R 1 , Q, y 2 , y 3 , Y 4 , U 5 , U 6 , U 8 , and R2 are as defined in the specification. The invention also provides pharmaceutical compositions comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, as defined in the specification, together with a pharmaceutically 10 acceptable carrier, diluent, or excipient. The invention also provides methods of inhibiting an MW-13 enzyme in an animal, comprising administering to the animal a compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention also provides methods of treating a disease mediated by an MNIP 13 enzyme in a patient, comprising administering to the patient a compound of Formula I, or a pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides methods of treating diseases such as heart disease, multiple sclerosis, osteo- and rheumatoid arthritis, arthritis other than osteo- or rheumatoid arthritis, cardiac insufficiency, inflammatory bowel disease, heart failure, age-related macular degeneration, chronic obstructive pulmonary disease, asthma, periodontal diseases, psoriasis, atherosclerosis, and osteoporosis in a patient, comprising administering to the patient a compound of Formula I, or a pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides combinations, comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, together with another pharmaceutically active component as described in the specification.
摘要翻译：本发明提供由式I定义的化合物或其药学上可接受的盐，其中R 1，Q，y 2，y 3，Y 4，U 5，U 6， 8>和R2如说明书中所定义。本发明还提供药物组合物，其包含本说明书中定义的式I化合物或其药学上可接受的盐以及药学上可接受的载体，稀释剂或赋形剂。本发明还提供了在动物中抑制MW-13酶的方法，包括向动物施用式I化合物或其药学上可接受的盐。本发明还提供了治疗由患者中的MNIP13酶介导的疾病的方法，包括单独或在药物组合物中向患者施用式I化合物或其药学上可接受的盐。本发明还提供了治疗诸如心脏病，多发性硬化，骨关节炎和类风湿性关节炎，除了骨关节炎或类风湿性关节炎之外的关节炎，心功能不全，炎性肠病，心力衰竭，年龄相关性黄斑变性，慢性阻塞性肺疾病，哮喘，牙周疾病，牛皮癣，动脉粥样硬化和骨质疏松症，包括单独或在药物组合物中向患者施用式I化合物或其药学上可接受的盐。本发明还提供了包含式I化合物或其药学上可接受的盐以及说明书中描述的另一种药物活性成分的组合。

10. 发明申请

WO2004014869A2 5,6-FUSED 3,4-DIHYDROPYRIMIDINE-2-ONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS 审中-公开
标题翻译：作为基质金属蛋白酶抑制剂的5,6-FUSED 3,4-二羟基嘧啶-2-酮衍生物
公开(公告)号：WO2004014869A2
公开(公告)日：2004-02-19
申请号：PCT/IB2003/003534
申请日：2003-08-04
申请人： WARNER-LAMBERT COMPANY LLC , NAHRA, Joe , O'BRIEN, Patrick, Michael , ORTWINE, Daniel, Fred
发明人： NAHRA, Joe , O'BRIEN, Patrick, Michael , ORTWINE, Daniel, Fred
IPC分类号： C07D239/00
CPC分类号： C07D231/12 , C07D233/56 , C07D239/74 , C07D239/80 , C07D249/08 , C07D401/06 , C07D401/12 , C07D403/06 , C07D405/06 , C07D471/04
摘要： This invention provides compounds defined by Formula (I), or a pharmaceutically acceptable salt thereof, wherein R 1 , Q, Y 3, Y 4 , Y 5 Y 6 , Y 8 , R 2 and R 4 are as defined in the specification. The invention also provides pharmaceutical compositions comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof, as defined in the specification, together with a pharmaceutically acceptable carrier, diluent, or excipient. The invention also provides methods of inhibiting an MMP-13 enzyme in an animal, comprising administering to the animal a compound of Formula (I), or a pharmaceutically acceptable salt thereof. The invention also provides methods of treating a disease mediated by an MMP-13 enzyme in a patient, comprising administering to the patient a compound of Formula (I), or a pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides methods of treating diseases such as heart disease, multiple sclerosis, osteo- and rheumatoid arthritis, arthritis other than osteo- or rheumatoid arthritis, cardiac insufficiency, inflammatory bowel disease, heart failure, age-related macular degeneration, chronic obstructive pulmonary disease, asthma, periodontal diseases, psoriasis, atherosclerosis, and osteoporosis in a patient, comprising administering to the patient a compound of Formula (I), or a pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides combinations, comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof, together with another pharmaceutically active component as described in the specification
摘要翻译：本发明提供式（I）所定义的化合物或其药学上可接受的盐，其中R 1，Q，Y 3，Y 4，Y 5 Y 6，Y 8， R 2和R 4如说明书中所定义。本发明还提供包含本说明书中定义的式（I）化合物或其药学上可接受的盐以及药学上可接受的载体，稀释剂或赋形剂的药物组合物。本发明还提供了在动物中抑制MMP-13酶的方法，包括向动物施用式（I）化合物或其药学上可接受的盐。本发明还提供了治疗患者中由MMP-13酶介导的疾病的方法，其包括向患者施用单独或药物组合物中的式（I）化合物或其药学上可接受的盐。本发明还提供了治疗诸如心脏病，多发性硬化，骨关节炎和类风湿性关节炎，除了骨关节炎或类风湿性关节炎之外的关节炎，心功能不全，炎性肠病，心力衰竭，年龄相关性黄斑变性，慢性阻塞性肺疾病，哮喘，牙周疾病，牛皮癣，动脉粥样硬化和骨质疏松症，其包括向患者单独或在药物组合物中给予式（I）化合物或其药学上可接受的盐。本发明还提供组合，其包含式（I）化合物或其药学上可接受的盐以及如说明书中所述的另一种药物活性成分

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式